Compare SST & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SST | LSTA |
|---|---|---|
| Founded | 2013 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.8M | 15.9M |
| IPO Year | 2020 | 2000 |
| Metric | SST | LSTA |
|---|---|---|
| Price | $1.70 | $1.03 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 55.6K | ★ 85.6K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $266,129,000.00 | $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.02 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $1.35 | $0.96 |
| 52 Week High | $6.05 | $5.07 |
| Indicator | SST | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 30.68 | 39.67 |
| Support Level | $1.68 | $0.97 |
| Resistance Level | $2.09 | $1.28 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 8.41 | 36.73 |
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It operate several flagship brands across multiple consumer verticals, including shopping, travel and search, and a customer acquisition and marketing platform powered by Artificial Intelligence and machine learning. The company's segment includes Marketing and Products. It generates maximum revenue from the Marketing segment. Geographically, it operates in United States and Other countries.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.